Comparing Gemcitabine Combinations for Pancreatic Cancer
Author Information
Author(s): Sultana Asma, Ghaneh Paula, Cunningham David, Starling Naureen, Neoptolemos John P, Smith Catrin Tudur
Primary Institution: CRUK Liverpool Cancer Trials Unit, Cancer Research Centre
Hypothesis
Which gemcitabine-based combination chemotherapy is most effective for advanced pancreatic cancer?
Conclusion
Gemcitabine combined with capecitabine or a platinum compound shows promising trends over gemcitabine combined with irinotecan or 5-fluorouracil.
Supporting Evidence
- Gemcitabine-based combinations have shown a survival advantage over single-agent gemcitabine.
- No particular combination was significantly superior to another.
- Trends suggest gemcitabine plus capecitabine or a platinum compound may be more effective than gemcitabine plus irinotecan.
Takeaway
This study looked at different combinations of a cancer drug called gemcitabine to see which one works best. It found that some combinations might be better than others.
Methodology
Adjusted indirect comparison method was used to assess randomized controlled trials of four gemcitabine-based combinations.
Potential Biases
Variations in patient characteristics and other prognostic factors may affect the results.
Limitations
The study relies on indirect comparisons due to a lack of direct head-to-head trials.
Participant Demographics
Patients with advanced pancreatic cancer, total of 4060 across 14 trials.
Statistical Information
Confidence Interval
95% CI 0.65 to 1.04; 95% CI 0.74 to 0.96; 95% CI 0.72 to 0.96
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website